[SCHEDULE 13G] Bionano Genomics, Inc. SEC Filing

Rhea-AI Filing Summary

Lincoln Alternative Strategies LLC reported beneficial ownership of 525,000 shares of Bionano Genomics, Inc. common stock, representing 5.42% of the 9,680,265 shares outstanding as of September 17, 2025. The filing indicates Lincoln has sole voting and dispositive power over these shares and states the holdings were not acquired to change or influence control of the issuer. The statement is submitted on a Schedule 13G under the Securities Exchange Act.

Positive

• Material disclosure of 5.42% ownership (525,000 shares) provides transparency to investors
• Sole voting and dispositive power is clearly stated, clarifying who controls the shares
• Filer certified that the holdings are not intended to change or influence control, consistent with passive intent

Negative

• None.

Insights

Financial Analyst

TL;DR: A passive investor disclosed a >5% stake, a material ownership disclosure but not an activist move.

Lincoln Alternative Strategies LLC holds 525,000 shares, equal to 5.42% of Bionano Genomics common stock, with sole voting and dispositive power. The filer certified the position is not intended to change or influence control, consistent with a passive Schedule 13G filing rather than an active Schedule 13D. For investors, this disclosure signals a meaningful minority stake that must be monitored for future filings if the position or intent changes.

Corporate Governance Expert

TL;DR: Governance-wise, this is a routine >5% disclosure without stated intent to exert control.

The filing identifies sole voting and dispositive authority for 5.42% of the outstanding shares and includes the required certification that the holdings are not for control purposes. No group affiliations or related-party arrangements are reported. This is a standard compliance disclosure that informs the register of substantial ownership while indicating no current governance challenge to management.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Bionano Genomics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

09075F404

(CUSIP Number)

09/17/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09075F404

1

Names of Reporting Persons

Lincoln Alternative Strategies LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 525,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 525,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

525,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.42 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Beneficial ownership percentage is based on 9,680,265 shares of the Issuer's common stock issued and outstanding as of September 17, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Bionano Genomics, Inc.
(b)	Address of issuer's principal executive offices: 9540 Towne Centre Drive, Suite 100, San Diego, CA, 92121
Item 2.
(a)	Name of person filing: Lincoln Alternative Strategies LLC
(b)	Address or principal business office or, if none, residence: 404 Washington Ave., Suite 650, Miami Beach, FL 33139
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 09075F404
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 525,000
(b)	Percent of class: 5.42%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 525,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 525,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lincoln Alternative Strategies LLC

Signature:	/s/ Stephen Temes
Name/Title:	Stephen Temes/Managing Member
Date:	09/17/2025

FAQ

What stake in BNGO does Lincoln Alternative Strategies LLC report?

Lincoln Alternative Strategies LLC reports beneficial ownership of 525,000 shares, representing 5.42% of outstanding common stock as of September 17, 2025.

Does Lincoln have voting control over the BNGO shares it holds?

Yes. The filing states Lincoln has sole voting power and sole dispositive power for the 525,000 shares.

Was this filing made as an activist attempt to change Bionano's control?

No. The certifying statement in the filing declares the securities were not acquired to change or influence control of the issuer.

Under which form was this ownership disclosed?

The position was disclosed on a Schedule 13G filed under the Securities Exchange Act.

What share count was used to calculate the 5.42% ownership?

The percentage is based on 9,680,265 shares of Bionano Genomics common stock issued and outstanding as of September 17, 2025.